Émilie Gobeil, Jérôme Bourgault, Patricia L Mitchell, Ursula Houessou, Eloi Gagnon, Arnaud Girard, Audrey Paulin, Hasanga D Manikpurage, Valérie Côté, Christian Couture, Simon Marceau, Yohan Bossé, Sébastien Thériault, Patrick Mathieu, Marie-Claude Vohl, André Tchernof, Benoit J Arsenault
BACKGROUND AND AIMS: RNA-based, antibody-based, and genome editing-based therapies are currently under investigation to determine if the inhibition of angiopoietin-like protein-3 (ANGPTL3) could reduce lipoprotein-lipid levels and atherosclerotic cardiovascular disease (ASCVD) risk. Mendelian randomisation (MR) was used to determine whether genetic variations influencing ANGPTL3 liver gene expression, blood levels, and protein structure could causally influence triglyceride and apolipoprotein B (apoB) levels as well as coronary artery disease (CAD), ischaemic stroke (IS), and other cardiometabolic diseases...
March 1, 2024: European Heart Journal